Mentioned in this article
Concert Pharmaceuticals Inc (CNCE) is around the top of the Biotechnology industry according to InvestorsObserver. CNCE received an overall rating of 79, which means that it scores higher than 79 percent of all stocks. Concert Pharmaceuticals Inc also achieved a score of 94 in the Biotechnology industry, putting it above 94 percent of Biotechnology stocks. Biotechnology is ranked 54 out of the 148 industries.
What do These Ratings Mean?
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 79 means the stock is more attractive than 79 percent of stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What’s Happening With Concert Pharmaceuticals Inc Stock Today?
Concert Pharmaceuticals Inc (CNCE) stock is trading at $8.38 as of 12:52 PM on Friday, Feb 24, a loss of -$0.01, or -0.12% from the previous closing price of $8.39. The stock has traded between $8.38 and $8.40 so far today. Volume today is below average. So far 283,258 shares have traded compared to average volume of 3,288,154 shares.
Click Here to get the full Stock Report for Concert Pharmaceuticals Inc stock.